These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 27098897)

  • 1. Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and PAC-QOL.
    Hatswell AJ; Vegter S
    Health Econ Rev; 2016 Dec; 6(1):14. PubMed ID: 27098897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
    Parker M; Haycox A; Graves J
    Pharmacoeconomics; 2011 Aug; 29(8):719-30. PubMed ID: 21635017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
    Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
    PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping EQ-5D utility scores from the Incontinence Quality of Life Questionnaire among patients with neurogenic and idiopathic overactive bladder.
    Kay S; Tolley K; Colayco D; Khalaf K; Anderson P; Globe D
    Value Health; 2013; 16(2):394-402. PubMed ID: 23538192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D.
    Versteegh MM; Leunis A; Luime JJ; Boggild M; Uyl-de Groot CA; Stolk EA
    Med Decis Making; 2012; 32(4):554-68. PubMed ID: 22114301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the 25-item National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25) to EQ-5D utility scores.
    Kay S; Ferreira A
    Ophthalmic Epidemiol; 2014 Apr; 21(2):66-78. PubMed ID: 24568628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing's syndrome (ERCUSYN).
    Badia X; Roset M; Valassi E; Franz H; Forsythe A; Webb SM
    Qual Life Res; 2013 Dec; 22(10):2941-50. PubMed ID: 23539468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.
    Madan J; Khan KA; Petrou S; Lamb SE
    Pharmacoeconomics; 2017 May; 35(5):549-559. PubMed ID: 28063083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
    Pennant M; Orlando R; Barton P; Bayliss S; Routh K; Meads C
    Health Technol Assess; 2011 May; 15 Suppl 1():43-50. PubMed ID: 21609652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective Observational Cohort Study of Japanese Patients With Cancer.
    Fumita S; Imai H; Harada T; Noriyuki T; Gamoh M; Akashi Y; Sato H; Kizawa Y; Tokoro A
    J Pain Symptom Manage; 2020 May; 59(5):1043-1051.e2. PubMed ID: 31805362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Severe Pain and Opioid-induced Constipation: An Observational Study of Quality of Life, Resource Use, and Costs in Sweden.
    Hjalte F; Ragnarson Tennvall G; Welin KO; Westerling D
    Pain Ther; 2016 Dec; 5(2):227-236. PubMed ID: 27830531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mapping analysis to estimate EQ-5D utility values using the COPD assessment test in Korea.
    Lim J; Choi SE; Bae E; Kang D; Lim EA; Shin GS
    Health Qual Life Outcomes; 2019 Jun; 17(1):97. PubMed ID: 31170982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating EQ-5D values from the Neck Disability Index and numeric rating scales for neck and arm pain.
    Carreon LY; Bratcher KR; Das N; Nienhuis JB; Glassman SD
    J Neurosurg Spine; 2014 Sep; 21(3):394-9. PubMed ID: 24905392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility.
    Lawson R; King F; Marsh K; Altincatal A; Cimen A
    Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping analysis to predict EQ-5D-5 L utility values based on the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) questionnaires in the Spanish population suffering from lower limb osteoarthritis.
    Martín-Fernández J; Morey-Montalvo M; Tomás-García N; Martín-Ramos E; Muñoz-García JC; Polentinos-Castro E; Rodríguez-Martínez G; Arenaza JC; García-Pérez L; Magdalena-Armas L; Bilbao A
    Health Qual Life Outcomes; 2020 Jun; 18(1):184. PubMed ID: 32539838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of utility index of quality of life (QOL) in prostate cancer patients: comparison of QOL utility index EuroQol-5D (EQ-5D) and visual analogue scale (VAS) with health-related QOL questionnaires SF-36 and EPIC].
    Akakura K; Matsuzaki K; Kobayashi T; Kitoh H; Mizoguchi K; Tomikawa G; Takura T; Kawabuchi K
    Nihon Hinyokika Gakkai Zasshi; 2011 Jan; 102(1):9-13. PubMed ID: 21520631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.